Evidence map›Paper›PMID 37596331›Full record

ArticleScientific reports2023

Curcumin and melphalan cotreatment induces cell cycle arrest and apoptosis in MDA-MB-231 breast cancer cells.

Carlos Luan A Passos, Renata Madureira Polinati, Christian Ferreira, Nathalia Alexia Nascimento Dos Santos, Daniel Galinis V Lima, Jerson Lima da Silva, Eliane Fialho

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Fortified Chestnut Honey Triggers Apoptosis in Colon Cancer Cells.Plant foods for human nutrition (Dordrecht, Netherlands) · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Novel cyclic CCancer cell international · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Carlos Luan A Passos *Functional Foods Laboratory, Nutrition Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Renata Madureira Polinati *Functional Foods Laboratory, Nutrition Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Christian Ferreira *Functional Foods Laboratory, Nutrition Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Nathalia Alexia Nascimento Dos SantosFunctional Foods Laboratory, Nutrition Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Daniel Galinis V LimaFunctional Foods Laboratory, Nutrition Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Jerson Lima da SilvaMedical Biochemistry Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Eliane FialhoFunctional Foods Laboratory, Nutrition Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. fialho@nutricao.ufrj.br.
Universidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the second most common type of cancer worldwide and the leading cause of cancer death in women. Dietary bioactive compounds may act at different stages of carcinogenesis, including tumor initiation, promotion, and progression. Spices have been used for thousands of years and have many bioactive compounds with chemopreventive and chemotherapeutic properties. Curcumin has a multitude of beneficial biological properties, including anti-inflammatory and anticancer effects. This study investigated the effects of cotreatment with curcumin and the chemotherapeutic drug melphalan in cultured MDA-MB-231 breast cancer cells. When used alone, both curcumin and melphalan had a cytotoxic effect on breast cancer cells. Combined treatment with 11.65 µM of curcumin and 93.95 µM of melphalan (CURC/MEL) reduced cell viability by 28.64% and 72.43% after 24 h and 48 h, respectively. CURC/MEL reduced the number of colony-forming units and increased ROS levels by 1.36-fold. CURC/MEL alter cell cycle progression, induce apoptosis, and upregulate caspases-3, -7, and -9, in MDA-MB-231 cells. Cotreatment with curcumin and melphalan have anti-breast cancer cells effects and represent a promising candidate for clinical testing.

Indexed as

Breast NeoplasmsCurcuminApoptosisCell Cycle CheckpointsFemaleHumansMelphalanCurcuminMelphalan

Identifiers

PMID37596331
PMCPMC10439215
OpenAlexW4385986308

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.